Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 12/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.44 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.43 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | MDM4 | O15151 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6434738 | 0.85 | ADORA3 (0.55) | ADORA3NPC1RAB9AABCG2MEN1 | |
| SCHEMBL1206235 | 0.85 | ADORA3 (0.55) | ADORA3NPC1RAB9AABCG2TMIGD3 | |
| SCHEMBL6439071 | 0.84 | ADORA3 (0.54) | ADORA3NPC1RAB9AABCG2MEN1 | |
| SCHEMBL5874038 | 0.83 | ADORA3 (0.62) | ADORA3NPC1RAB9AABCG2TMIGD3 | |
| SCHEMBL6435371 | 0.82 | ADORA3 (0.52) | ADORA3NPC1RAB9AABCG2TMIGD3 | |
| SCHEMBL6435363 | 0.82 | CSF1R (0.53) | ADORA3NPC1RAB9AABCG2TMIGD3 | |
| SCHEMBL6435943 | 0.81 | ADORA3 (0.51) | ADORA3NPC1RAB9ATMIGD3HTT | |
| SCHEMBL18666640 | 0.81 | RAB9A (0.52) | ADORA3NPC1RAB9AKMT2AHTT | |
| SCHEMBL1206294 | 0.77 | ADORA3 (0.47) | ADORA3NPC1RAB9AABCG2TMIGD3 | |
| SCHEMBL6436826 | 0.77 | ADORA3 (0.49) | ADORA3NPC1RAB9AABCG2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963304-B2 | ISOQUINOLINE DERIVATIVES | MSD OSS BV (NL) | 2015-05-13 | — | — | EP | disclosed |
| US-7893088-B2 | 6-substituted isoquinoline derivatives | N.V. ORGANON (NL) | 2011-02-22 | — | — | US | disclosed |
| EP-2054389-B1 | 6-SUBSTITUTED ISOQUINOLINE DERIVATIVES AS ROCK-1 INHIBITORS | ORGANON NV (NL) | 2010-04-07 | — | — | EP | disclosed |
| US-7618985-B2 | Isoquinoline derivatives | N.V. ORGANON (NL) | 2009-11-17 | — | — | US | disclosed |
| EP-1963304-B1 | ISOQUINOLINE DERIVATIVES | ORGANON NV (NL) | 2009-06-24 | — | — | EP | disclosed |
| EP-2054389-A1 | 6-SUBSTITUTED ISOQUINOLINE DERIVATIVES AS ROCK-1 INHIBITORS | N.V. Organon (NL) | 2009-05-06 | — | — | EP | disclosed |
| EP-1963304-A1 | ISOQUINOLINE DERIVATIVES | N.V. Organon (NL) | 2008-09-03 | — | — | EP | disclosed |
| WO-2008020081-A1 | 6-SUBSTITUTED ISOQUINOLINE DERIVATIVES AS ROCK-1 INHIBITORS | N.V. ORGANON (NL) | 2008-02-21 | — | — | WO | disclosed |
| US-20080045566-A1 | 6-SUBSTITUTED ISOQUINOLINE DERIVATIVES | N.V. ORGANON (NL) | 2008-02-21 | — | — | US | disclosed |
| WO-2007065916-A1 | ISOQUINOLINE DERIVATIVES | N.V. ORGANON (NL) | 2007-06-14 | — | — | WO | disclosed |
| US-20070135479-A1 | Isoquinoline derivatives | N.V. ORGANON (NL) | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135479-A1 | Isoquinoline derivatives | ROCK1, ROCK2, RHOA | ADORA3 1462/4885NPC1 108/4885RAB9A 831/4885 |
| US-20080045566-A1 | 6-SUBSTITUTED ISOQUINOLINE DERIVATIVES | ROCK1, ROCK2, RHOA | ADORA3 1508/4885NPC1 47/4885RAB9A 470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.